$ALDX
Aldeyra Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024123248 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.696M
YoY Change 42.71%
% of Gross Profit
Research & Development $12.44M
YoY Change 78.71%
% of Gross Profit
Depreciation & Amortization $62.99K
YoY Change -10.01%
% of Gross Profit
Operating Expenses $12.44M
YoY Change 78.71%
Operating Profit -$16.14M
YoY Change 68.97%
Interest Expense $1.025M
YoY Change 90.18%
% of Operating Profit
Other Income/Expense, Net $1.025M
YoY Change -24.86%
Pretax Income -$15.11M
YoY Change 84.53%
Income Tax
% Of Pretax Income
Net Earnings -$15.11M
YoY Change 84.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.25
Diluted Earnings Per Share -$0.25
COMMON SHARES
Basic Shares Outstanding 59.55M 59.42M
Diluted Shares Outstanding 59.53M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $112.7M
YoY Change -21.34%
Cash & Equivalents $68.12M
Short-Term Investments $44.62M
Other Short-Term Assets $3.977M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $116.7M
YoY Change -20.71%
LONG-TERM ASSETS
Property, Plant & Equipment $1.360K
YoY Change -82.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $267.3K
YoY Change
Total Long-Term Assets $598.6K
YoY Change 728.69%
TOTAL ASSETS
Total Short-Term Assets $116.7M
Total Long-Term Assets $598.6K
Total Assets $117.3M
YoY Change -20.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $186.9K
YoY Change -24.38%
Accrued Expenses $10.42M
YoY Change 32.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $280.0K
YoY Change -97.92%
Total Short-Term Liabilities $17.15M
YoY Change -20.65%
LONG-TERM LIABILITIES
Long-Term Debt $15.00M
YoY Change 464.51%
Other Long-Term Liabilities $70.23K
YoY Change
Total Long-Term Liabilities $15.00M
YoY Change 464.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.15M
Total Long-Term Liabilities $15.00M
Total Liabilities $32.22M
YoY Change 32.75%
SHAREHOLDERS EQUITY
Retained Earnings -$434.3M
YoY Change 11.5%
Common Stock $519.3M
YoY Change 1.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.10M
YoY Change
Total Liabilities & Shareholders Equity $117.3M
YoY Change -20.34%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$15.11M
YoY Change 84.6%
Depreciation, Depletion And Amortization $62.99K
YoY Change -10.01%
Cash From Operating Activities -$7.975M
YoY Change -0.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.263M
YoY Change
Cash From Investing Activities $5.263M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -197.4K
YoY Change -38.32%
NET CHANGE
Cash From Operating Activities -7.975M
Cash From Investing Activities 5.263M
Cash From Financing Activities -197.4K
Net Change In Cash -2.910M
YoY Change -65.15%
FREE CASH FLOW
Cash From Operating Activities -$7.975M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001341235
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36332
dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1968197
dei Entity Address Address Line1
EntityAddressAddressLine1
131 Hartwell Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
761-4904
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ALDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59549598
CY2024Q3 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
28120029
CY2023Q4 aldx Cash And Money Market Funds
CashAndMoneyMarketFunds
142823016
CY2024Q3 aldx Cash Equivalent Reverse Repurchase Agreements
CashEquivalentReverseRepurchaseAgreements
40000000
CY2023Q4 aldx Cash Equivalent Reverse Repurchase Agreements
CashEquivalentReverseRepurchaseAgreements
0
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
44624170
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3976564
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4987317
CY2024Q3 us-gaap Assets Current
AssetsCurrent
116720763
CY2023Q4 us-gaap Assets Current
AssetsCurrent
147810333
CY2024Q3 us-gaap Deferred Costs
DeferredCosts
267261
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
0
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
329968
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
510814
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1360
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5764
CY2024Q3 us-gaap Assets
Assets
117319352
CY2023Q4 us-gaap Assets
Assets
148326911
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
186919
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1338057
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10423297
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5536464
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
279957
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
15146546
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
263241
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
239183
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6000000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17153414
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22260250
CY2024Q3 us-gaap Deferred Long Term Liability Charges
DeferredLongTermLiabilityCharges
0
CY2023Q4 us-gaap Deferred Long Term Liability Charges
DeferredLongTermLiabilityCharges
6000000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
70234
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
271631
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15000000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2024Q3 us-gaap Liabilities
Liabilities
32223648
CY2023Q4 us-gaap Liabilities
Liabilities
28531881
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59549598
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59549598
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59195951
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59195951
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
59550
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
59196
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
519271439
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
513994982
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
66540
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-434301825
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394259148
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
85095704
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
119795030
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117319352
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
148326911
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12441509
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6961669
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33594761
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25160437
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3696067
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2588701
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9944487
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11535868
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16137576
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9550370
us-gaap Operating Income Loss
OperatingIncomeLoss
-43539248
us-gaap Operating Income Loss
OperatingIncomeLoss
-36696305
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1503845
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1902242
us-gaap Investment Income Interest
InvestmentIncomeInterest
4951949
us-gaap Investment Income Interest
InvestmentIncomeInterest
5463928
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
479252
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
538743
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1455378
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1557171
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1024593
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1363499
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3496571
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3906757
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-15112983
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8186871
us-gaap Net Income Loss
NetIncomeLoss
-40042677
us-gaap Net Income Loss
NetIncomeLoss
-32789548
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59530113
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59530113
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58990189
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58990189
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59453312
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59453312
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58858631
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58858631
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-15112983
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8186871
us-gaap Net Income Loss
NetIncomeLoss
-40042677
us-gaap Net Income Loss
NetIncomeLoss
-32789548
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
76198
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
66540
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
103938
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
76198
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
66540
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
103938
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15036785
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8186871
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39976137
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32685610
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
119795030
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5238751
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
38060
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
66540
aldx Net Loss
NetLoss
-40042677
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
85095704
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151008029
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4943228
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
163941
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
111102
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
532951
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
103938
aldx Net Loss
NetLoss
-32789548
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
123007739
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
98310339
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1802281
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
19869
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
76198
CY2024Q3 aldx Net Loss
NetLoss
-15112983
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
85095704
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
129883199
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1627170
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
158648
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
58544
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
532951
CY2023Q3 aldx Net Loss
NetLoss
-8186871
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
123007739
us-gaap Profit Loss
ProfitLoss
-40042677
us-gaap Profit Loss
ProfitLoss
-32789548
us-gaap Share Based Compensation
ShareBasedCompensation
6710160
us-gaap Share Based Compensation
ShareBasedCompensation
6553112
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
133411
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
283444
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1205746
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
14542
us-gaap Depreciation
Depreciation
185250
us-gaap Depreciation
Depreciation
196311
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1010753
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2847103
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1151138
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
113569
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3188085
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8016017
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31171902
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30826568
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
75351884
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
32000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43351884
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-217261
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
163941
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
-0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
532951
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
38060
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
111102
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-179201
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-257908
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-74702987
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1084476
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
142823016
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144419364
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68120029
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143334888
us-gaap Interest Paid Net
InterestPaidNet
1329167
us-gaap Interest Paid Net
InterestPaidNet
1262354
aldx Offering Cost Not Yet Paid
OfferingCostNotYetPaid
50000
aldx Offering Cost Not Yet Paid
OfferingCostNotYetPaid
0
us-gaap Nature Of Operations
NatureOfOperations
<div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NATURE OF BUSINESS </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aldeyra Therapeutics, Inc., together with its wholly owned subsidiaries (the “Company” or “Aldeyra”), a Delaware corporation, is a clinical-stage biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s principal activities to date include research and development activities along with related general business planning, including raising capital.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company’s management evaluates estimates and assumptions on an ongoing basis. Management’s most significant estimates in the Company’s condensed consolidated financial statements include, but are not limited to, deferred and accrued research and development costs, stock-based compensation, and accounting for income taxes and related valuation allowance. Although the estimates and assumptions are based on the Company’s knowledge of current events and actions the Company may undertake in the future, actual results may ultimately materially differ from the estimates and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8637750
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8637750
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7200692
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7200692
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68120029
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
44624170
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
97338714
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14312565
CY2024Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2024Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2830668
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4463783
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
725242
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
340388
CY2024Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
420654
CY2023Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
183146
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3976564
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4987317
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4282902
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3087937
CY2024Q3 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5483521
CY2023Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1687327
CY2024Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
656874
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
761200
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10423297
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5536464
CY2024Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2024Q3 aldx Supplemental End Of Term Charges
SupplementalEndOfTermCharges
282286
CY2023Q4 aldx Supplemental End Of Term Charges
SupplementalEndOfTermCharges
173646
CY2024Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
2329
CY2023Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
27100
CY2024Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
279957
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
15146546
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15000000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
292500
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
15300000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
15592500
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
300000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3225794
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
789217
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6710162
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6553112
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5868816
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.4
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M8D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3996
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2376328
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
179897
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.9
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
31506
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.49
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8033741
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.57
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M8D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7387843
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5116768
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M3D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3509500
CY2024Q3 us-gaap Share Price
SharePrice
5.39
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
944497
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.3
aldx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Settled In Common Stock In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod
-340488
aldx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Settled In Common Stock Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue
5.1
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
604009
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.41
CY2024Q3 aldx Unamortized Right Of Use Asset
UnamortizedRightOfUseAsset
400000
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
354169
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
20694
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
333475
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
263241
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
70234
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
333475
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
354169
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
68964
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
285205
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2024Q3 aldx Indemnification Obligations Claims Outstanding
IndemnificationObligationsClaimsOutstanding
0
CY2024Q3 aldx Cash Reserve For Indemnities And Guarantees
CashReserveForIndemnitiesAndGuarantees
0
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-123248-index-headers.html Edgar Link pending
0000950170-24-123248-index.html Edgar Link pending
0000950170-24-123248.txt Edgar Link pending
0000950170-24-123248-xbrl.zip Edgar Link pending
aldx-20240930.htm Edgar Link pending
aldx-20240930.xsd Edgar Link pending
aldx-ex10_3.htm Edgar Link pending
aldx-ex10_4.htm Edgar Link pending
aldx-ex31_1.htm Edgar Link pending
aldx-ex31_2.htm Edgar Link pending
aldx-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
aldx-20240930_htm.xml Edgar Link completed
img130890548_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending